Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seaside Therapeutics LLC

www.seasidetherapeutics.com

Latest From Pharmacia Biotech Inc.

Bifurcated Biotech

Nycomed wants to duplicate the success of rival PE Corp. by expanding its role as a supplier of knowledge-oriented products. It already has a play in gene-based drug discovery including a high-throughput gene sequencing system and SNP analysis technologies.
BioPharmaceutical Strategy

A First Pass at the Proteome

Proteomics is the new buzzword for an old concept—the analysis of all cellular proteins in parallel. But the field has been revitalized by the assembly of large-scale gene sequence databases, and progress in mass spectrometry techniques for identifying proteins. Will the proteomics companies generate the kind of high-valuation discovery- and information-based businesses that genomics companies have?
BioPharmaceutical Research and Development Strategies

DNA-Chips in Genomics

DNA chips have application as high-througput assays to determine the function of genes. The chips can also speed positional cloning. Development agreements with pharmaceutical partners should illuminate the DNA chips’ real abilities and applications. Coupled with strong bioinformatics, gene expression microarrays will produce the next generation of genomic databases.
BioPharmaceutical Platform Technologies

The DNA-Chip in Diagnostics

Over the last 5-years the DNA probe array for diagnostics has moved from concept to market. But opportunities in infectious disease are limited, and the opportunity at the point-of-care is still evolving. Meanwhile, ripe opportunities and big valuations in genomics are luring DNA-chip companies away from diagnostics. Oligonucleotide arrays should have a role to play in linking outcomes to genes in AIDS and cancer.
Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Seaside Therapeutics LLC
  • Senior Management
  • Randall L Carpenter, MD, Pres. & CEO
    Aileen M Healy, PhD, VP, Research
    Paul P Wang, MD, VP, Clin. Dev.
  • Contact Info
  • Seaside Therapeutics LLC
    Phone: (617) 374-9009
    840 Memorial Dr.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register